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Abstract  
 
Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in 
tumour progression, and is one of several growth factors with a central role in ovarian 
carcinogenesis.  We hypothesised that common single nucleotide polymorphisms 
(SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to 
ovarian cancer.  We analysed 25 FGF2 tgSNPs using five independent study 
populations from the United States and Australia.  Analysis was restricted to non-
Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 
controls).  There were no statistically significant associations between any FGF2 
SNPs and ovarian cancer risk.  There were two nominally statistically significant 
associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; 
p<0.05) and serous ovarian cancer risk in the combined dataset, but rare homozygous 
estimates did not achieve statistical significance, nor were they consistent with the log 
additive model of inheritance.  Overall genetic variation in FGF2 does not appear to 
play a role in susceptibility to ovarian cancer.   
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Ovarian cancer is the seventh leading cause of cancer mortality among women 
globally, accounting for 4.2% of cancer deaths (Parkin et al., 2005).  Lethality of 
ovarian cancer is due in part to the absence of symptoms in the majority of cases who 
typically present with metastatic disease that has spread outside the pelvis (Cannistra, 
1993).  The lack of practical screening methods and detectable symptoms in the early 
stages of tumour progression underscore the importance of a better understanding of 
the molecular aspects of disease to effective prevention and treatment (Wenham et al., 
2002).  Although the aetiology of ovarian cancer has not been fully elucidated, it is 
generally agreed that family history of ovarian or breast cancer is the most important 
risk factor for epithelial ovarian cancer (Whittemore, 1994).  Hereditary ovarian 
cancers occurring in breast/ovarian cancer families have been linked to mutations in 
the BRCA1 and BRCA2 genes, while cases occurring in association with Lynch 
syndrome have been linked to mutations in MSH2 and MLH1 (Boyd & Rubin, 1997; 
Pharoah & Ponder, 2002).  Given that only 3-5% of cases present as high-risk familial 
cases (Wenham et al., 2002), it is plausible that several low-penetrance genes with 
relatively common alleles may account for a portion of the increased risk.   
 
Fibroblast growth factor (FGF)-2 (basic) has been localized to 4q26-q27 and is a 
member of a large family of structurally related proteins that affect the growth and 
differentiation, migration and survival of a wide variety of cell types. It is highly 
conserved among eukaryotes with sequence homology of >90% across a wide range of 
species (Bikfalvi et al., 1997).  FGF2 is a potent angiogenic molecule and has been 
shown to induce migration and proliferation of endothelial cells which differentiate 
into new vascular structures (Folkman & Klagsbrun, 1987).  Inactivation of FGF2 in 
vivo  has been shown to suppress tumour growth through the inhibition of FGF2-
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induced angiogenesis (Hori et al., 1991).  Elevated levels of urinary FGF2 were shown 
to correlate significantly with metastatic disease in a wide range of cancers including 
ovarian tumours (Nguyen et al., 1994).  Expression studies in ovarian cancer cell lines 
have also demonstrated significant increases in mRNA expression of the FGF2 
receptor, as well as dose-dependent increased cell numbers in response to exogenous 
stimulation by FGF2 (Crickard et al., 1994).  In addition, gene expression profiling of 
advanced ovarian tumours indicates that FGF2 signalling plays a central role 
throughout the carcinogenesis process (De Cecco et al., 2004). 
 
We hypothesised that common single nucleotide polymorphisms (SNPs) in the FGF2 
gene may alter the angiogenic potential of FGF2 and thereby susceptibility to ovarian 
cancer.  While there is much evidence that FGF2 is functionally relevant to tumour 
development and metastasis, to the best of our knowledge no study to date has 
assessed common variations in this gene for a possible association with ovarian cancer 
susceptibility.  The current study evaluates twenty-five FGF2 SNPs for an association 
with ovarian cancer risk, and represents a collaborative effort using data from five 
case-control studies from the United States and Australia, all participants in the 
Ovarian Cancer Association Consortium (OCAC) (Gayther et al., 2000). OCAC is an 
international collaboration established to provide a forum for researchers to evaluate 
genetic associations with ovarian cancer with increased power.   
 
Material and methods 
Study Population 
Details of study design, and case and control ascertainment for each study included in 
this analysis are summarized in Table 1.  A total of five ovarian cancer case-control 
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studies contributed data to this analysis, four of which used population-based 
ascertainment methods and one (MAYO) that was clinic-based (Table 1). Individuals 
with missing data on tumour behaviour, histology or race, and controls with prior 
oophorectomies, were excluded from the analysis.  The final combined dataset 
comprised 1457 serous invasive cases and 3137 controls, the majority of whom were 
reported to be non-Hispanic Whites.  All studies have been previously described 
elsewhere (Merritt et al., 2007; Pearce et al., 2008; Pike et al., 2004; Rossing et al., 
2007; Sellers et al., 2008).  Approval from respective human research ethics 
committees was obtained, and all participants provided written informed consent.   
“Table 1 about here” 
 
Single Nucleotide Polymorphism Selection and Genotyping 
Genotype data for this analysis was obtained from two 1536-SNP Illimina Golden 
Gate Assays™ conducted at two OCAC centres: AOCS-ACS and MAYO samples 
were genotyped at the Queensland Institute of Medical Research (QIMR), 
Queensland, Australia; DOVE, HOPE and USC samples were genotyped at the 
University of Southern California (USC) Epigenome Center, California, USA.  
Genotyping was conducted according to customized GoldenGate genotyping 
procedures (Illumina Inc.).   
 
At QIMR we examined genotypes within 5 kb of FGF2 (June 2006) from the projects 
of the HapMap Consortium ("The International HapMap Project," 2003), Perlegen 
(Hinds et al., 2005), NIEHS SNPs, and SeattleSNPs {http://pga.mbt.washington.edu/} 
and found  HapMap to be the most informative for European-American samples using 
the binning algorithm of ldSelect (Carlson et al., 2004) to identify tagging SNPs 
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(tgSNPs) for SNPs with r2 > 0.8 and minor allele frequencies (MAFs) > 0.05.  Fifty-
eight SNPs were sorted into 20 bins, yielding 20 tgSNPs, 2 of which failed assay 
conversion.  At USC we selected tgSNPs for FGF2 (including putative regulatory 
regions 20kb up and 10kb downstream of the gene) using the program SNAGGER 
(Edlund et al., 2008).  We attempted to tag all SNPs in HapMap (Release #21 July 
2006) in the CEU population with a MAF of 0.05 or greater with an r2 > 0.8.   
 
A total of 25 FGF2 SNPs were selected across both collaborations, 17 of which were 
genotyped for all studies, one was genotyped for the AOCS-ACS and MAYO studies 
only and seven were genotyped for DOVE, HOPE and UCS studies only (Table 2).  
The performance of our selected tgSNPs in capturing known common variation across 
the FGF2 gene was evaluated using Tagger (de Bakker et al., 2005) implemented in 
Haploview (Barrett et al., 2005).  We estimate that 97% of the known common 
variants (MAF ≥ 0.05) across the FGF2 locus (including 20kb 5’ and 10 kb 3’ of the 
gene) have been captured by these SNPs.   
 
Samples with call rates below 95% (or 90%), and SNPs with call rates below 98% (or 
95%), were excluded at QIMR (and USC).  At QIMR, SNPs with GenTrain scores < 
0.5 were manually checked and adjusted according to Illumina guidelines; all SNPs 
were manually checked at USC. Greater than 97% and 93% at of SNPs passed this 
initial quality assurance at QIMR and USC respectively.  Two samples per 96 well 
plate were blindly duplicated (n=20).  One inter- and one intra-plate duplicate samples 
were included on each plate to assist with genotype calling and ensuring against plate 
flips.  In addition, 128 blinded duplicate samples were included at USC.  Genotyping 
quality was also assessed using tests for Hardy-Weinberg equilibrium (HWE). SNPs 
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with significant deviations from HWE in controls (0.001<P<0.05) were assessed and 
the genotype data was excluded if the clustering was found to be suboptimal.  SNPs 
with HWE P<0.001 were excluded from the analysis.  Overall, >84% and 91% of 
SNPs passed all quality assurance criteria at QIMR and USC, respectively. 
 
 
Statistical Analysis  
Case-control analyses were restricted to White non-Hispanic women with serous 
invasive ovarian tumours.  White women participating in Australian studies were 
assumed to be non-Hispanic.  Genotype frequencies in non-Hispanic White controls 
for each FGF2 SNP were assessed for departure from HWE using the χ2 goodness-of-
fit test.  Each of the five contributing case-control studies was assessed for differences 
in age at interview among controls and age at diagnosis among cases using Student’s 
t-test for comparison of means.  The MAF for each SNP was estimated from the 
control population for each study.   
 
The combined odds ratios (ORs) and their 95% confidence intervals (95% CIs) were 
obtained from unconditional logistic regression models.  Assuming a log additive 
model of inheritance, the per-allele risks associated with serous invasive tumours 
among non-Hispanic Whites for each of the 25 FGF2 SNP were estimated by fitting 
the number of rare alleles carried as a continuous covariate. All estimates were 
adjusted for study site, and age at diagnosis for cases or age at interview for controls.  
All tests for association were two-tailed and statistical significance was assessed at 
p<0.05 using STATA v. 9.0 (StataCorp, USA). 
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Results 
Details of study design, and case and control ascertainment for each contributing study 
are summarized in Table 1.  Genotype data across the different studies met the 
minimum quality assurance measure for inclusion in the analysis, with the exception 
of rs17473132 SNP which was out of HWE in the USC study (p=0.0002), resulting in 
the exclusion of 374 genotypes for this SNP from the final dataset.  Cases were 
significantly more likely to be older than controls (p <0.0001), and ranged in age at 
diagnosis from 23.6 to 86 years (mean age 60.1 ± 10.3) while controls ranged in age at 
interview from 19.2 to 91 years (mean age 56.9 ± 11.2; see Table 1).   
 
Estimates for the 25 FGF2 SNPs and risk of invasive serous tumours were calculated 
among non-Hispanic White women, based on genotype data from a combined total of 
1269 serous invasive cases and 2829 controls genotyped at both sites (Table 2).  None 
of the 25 SNPs analysed were significantly associated with risk of ovarian cancer 
although, without correcting for multiple testing, two SNPs showed borderline 
evidence of an association.  The per-allele estimate for the rs308447 SNP showed a 
borderline significant inverse association with serous tumours [ORper-allele = 0.87 (0.76 
- 1.00), p = 0.04].  However, although the heterozygous estimate supports an 
association [ORHet = 0.72 (0.59 – 0.87) p = 0.001], the odds ratio for rare homozygotes 
was neither statistically significant (p>0.4) nor consistent with the log additive model 
of inheritance.  Similarly the rs308379 SNP was inversely associated with serous 
tumours among heterozygotes [ORHet = 0.85 (0.74 – 0.98) p = 0.03] but no equivalent 
association was observed among rare homozygotes (p= 0.59), nor were the estimates 
consistent with the log additive model of inheritance (Table 2). These observations are 
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likely to be due to chance alone, and we therefore conclude that there is no association 
between any of these 25 SNPs in FGF2 and risk of invasive serous ovarian cancer in 
non-Hispanic White women. 
“Table 2 about here” 
 
Discussion 
FGF2 is a potent angiogenic molecule that has been shown to promote tumour cell 
mitosis and has been implicated in the differentiation of stromal and epithelial cells 
from a dormant to an invasive phenotype (Dow et al., 2000).  We have evaluated the 
effects of 25 SNPs in the FGF2 gene on the risk of invasive serous ovarian cancer in 
non-Hispanic White women enrolled in five case-control studies from the United 
States and Australia, and found no convincing evidence of an association of any FGF2 
SNPs with serous ovarian tumours in our combined dataset.  We acknowledge that the 
potential for variation in estimates is inherent in analyses involving samples from 
different countries, given the likelihood of differences in case-control selection criteria 
and population differences attributable to environmental factors or genetic 
background.  However, all contributing studies included in our analysis selected 
controls from the same source population as cases, participants were predominantly 
non-Hispanic White (Table 1), and indeed there was no evidence of heterogeneity 
between the studies (non-Hispanic Whites only) for any of the SNPs included in this 
analysis (PHeterogeneity ≥0.14). 
 
The human FGF2 gene encompasses 71.53 kb of genomic sequences on chromosome 
4.  Using Hapmap SNP genotype frequency data for FGF2 SNPs, we estimated that 
the 25 SNPs presented in this report capture 97% of the known common variation 
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(MAF ≥ 0.05) across the FGF2 locus at r2 ≥ 0.8 for pairwise correlations.  To the best 
of our knowledge, this is the first study to evaluate FGF2 SNPs in a large multi-center 
study.  Based on the method of Purcell et al (Purcell et al., 2003) we estimated that we 
had ≥80% power to detect ORs of 1.20 at an alpha of 0.05 for the 19 SNPs with MAFs 
≥0.1 (Table 2).  However, we acknowledge that we had considerably less power to 
detect these effect sizes with the six SNPs with MAFs < 0.1. 
 
Our study highlights the importance of consortium-based approaches to investigating 
putative genetic association in case-control analyses, particularly for low-risk genes 
that require large sample sizes to detect small SNP effects.  We note that three SNPs, 
in addition to the rs308447, achieved the minimal level of significance of p≤0.05 in 
study-specific per-allele estimates (data not shown), but not in the combined analysis.  
If we had reported the results of these individual case-control studies, it may have led 
other groups to attempt replication but our combined analysis provides a more 
accurate assessment of these associations and reduces publication bias.   
 
FGF2 has been the focus of a plethora of studies into human tumour biology and has 
important implications for cancer therapies and clinical outcomes.   FGF2 is one of 
several fibroblast growth factor molecules that interact with various vascular 
endothelial growth factors and cell surface receptors that are known to play a role in 
tumour growth and angiogenesis (Powers et al., 2000; Presta et al., 2005).  The 
correlation between angiogenesis and the extent of metastatic disease has been widely 
demonstrated in a large and diverse range of human cancers (Macchiarini et al., 1992; 
Weidner et al., 1993; Weidner et al., 1991) including advanced stage ovarian 
carcinoma (Hollingsworth et al., 1995; Weidner, 1995).  Abnormally high 
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concentrations of FGF2 have been found in the serum of patients with active 
metastatic cancers and have been shown to correlate significantly with extent of 
disease, clinical status and risk of future mortality (Nguyen et al., 1994).  These 
findings would support the assessment of FGF2 polymorphisms with regard to 
ovarian cancer survival and prognosis in future studies.  To date several functional 
angiogenic gene SNPs have been studied in solid cancers with varying results derived 
from sample sizes that are too small to detect the modest effects anticipated from these 
low penetrance genes (Balasubramanian et al., 2002).    Large-scale epidemiologic 
studies of other genes involved in angiogenesis are therefore warranted to further 
enhance our understanding of tumour progression.  This could lead to novel 
approaches to risk stratification or the use of anti-angiogenic treatment strategies, if 
angiogenic potential, and hence prognosis, can be predicted according to individual 
genotype.  
 
 13
Acknowledgement 
The AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. 
Gertig, A. Green, P. Webb) gratefully acknowledges the contribution of all the clinical 
and scientific collaborators (see http://www.aocstudy.org/). The AOCS and ACS 
Management Group (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) 
thank all of the project staff and collaborating institutions. We also thank all the 
participants in all the participating studies.  
 
Grant support:  National Health and Medical Research Council of Australia (199600, 
ACS study; GCT and PW), U.S. Army Medical Research and Materiel Command 
under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of 
Western Australia (AOCS study); and NIH R01 CA122443, R01 CA112523 and R01 
CA87538 (DOVE study; JAD and MAR); the Mayo Foundation (MAYO study; EG, 
DR, RV, SA).  Some of this work was funded by the California Cancer Research 
Program grants 00-01389V-20170 and 2110200, U.S. Public Health Service grants 
CA14089, CA17054, CA61132, CA63464, N01-PC-67010 and R03-CA113148, and 
California Department of Health Services sub-contract 050-E8709 as part of its state-
wide cancer reporting program 
 14
References 
Balasubramanian, S. P., Brown, N. J., & Reed, M. W. (2002). Role of genetic 
polymorphisms in tumour angiogenesis. British Journal of Cancer, 87(10), 1057-
1065. 
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: analysis and 
visualization of LD and haplotype maps. Bioinformatics, 21(2), 263-265. 
Bikfalvi, A., Klein, S., Pintucci, G., & Rifkin, D. B. (1997). Biological roles of 
fibroblast growth factor-2. Endocrine Reviews, 18(1), 26-45. 
Boyd, J., & Rubin, S. C. (1997). Hereditary ovarian cancer: molecular genetics and 
clinical implications. Gynecologic Oncology, 64(2), 196-206. 
Cannistra, S. A. (1993). Cancer of the ovary. New England Journal of Medicine, 
329(21), 1550-1559. 
Carlson, C. S., Eberle, M. A., Rieder, M. J., Yi, Q., Kruglyak, L., & Nickerson, D. A. 
(2004). Selecting a Maximally Informative Set of Single-Nucleotide Polymorphisms 
for Association Analyses Using Linkage Disequilibrium. The American Journal of 
Human Genetics, 74(1), 106-120. 
Crickard, K., Gross, J. L., Crickard, U., Yoonessi, M., Lele, S., Herblin, W. F., et al. 
(1994). Basic fibroblast growth factor and receptor expression in human ovarian 
cancer. Gynecologic Oncology, 55(2), 277-284. 
de Bakker, P. I., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. 
(2005). Efficiency and power in genetic association studies. Nature Genetics, 37(11), 
1217-1223. 
De Cecco, L., Marchionni, L., Gariboldi, M., Reid, J. F., Lagonigro, M. S., Caramuta, 
S., et al. (2004). Gene expression profiling of advanced ovarian cancer: 
 15
characterization of a molecular signature involving fibroblast growth factor 2. 
Oncogene, 23(49), 8171-8183. 
Dow, J. K., & deVere White, R. W. (2000). Fibroblast growth factor 2: its structure 
and property, paracrine function, tumour angiogenesis, and prostate-related mitogenic 
and oncogenic functions. Urology, 55(6), 800-806. 
Edlund, C., Lee, W., Li, D., Van Den Berg, D., & Conti, D. (2008). Snagger: A user-
friendly program for incorporating additional information for tagSNP selection. BMC 
Bioinformatics, 9(1), 174. 
Folkman, J., & Klagsbrun, M. (1987). Angiogenic factors. Science, 235(4787), 442-
447. 
Gayther, S. A., de Foy, K. A., Harrington, P., Pharoah, P., Dunsmuir, W. D., Edwards, 
S. M., et al. (2000). The frequency of germ-line mutations in the breast cancer 
predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer 
Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer 
Study Collaborators. Cancer Research, 60(16), 4513-4518. 
Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., et 
al. (2005). Whole-genome patterns of common DNA variation in three human 
populations. Science, 307(5712), 1072-1079. 
Hollingsworth, H. C., Kohn, E. C., Steinberg, S. M., Rothenberg, M. L., & Merino, M. 
J. (1995). Tumour angiogenesis in advanced stage ovarian carcinoma. American 
Journal of Pathology, 147(1), 33-41. 
Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., et al. (1991). 
Suppression of solid tumour growth by immunoneutralizing monoclonal antibody 
against human basic fibroblast growth factor. Cancer Research, 51(22), 6180-6184. 
The International HapMap Project. (2003). Nature, 426(6968), 789-796. 
 16
Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F., & Angeletti, C. A. (1992). 
Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 
340(8812), 145-146. 
Merritt, M. A., Green, A. C., Nagle, C. M., & Webb, P. M. (2007). Talcum powder, 
chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian 
cancer. International Journal of Cancer, 122(1), 170-176. 
Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. 
(1994). Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the 
urine of patients with a wide spectrum of cancers. Journal of the National Cancer 
Institute, 86(5), 356-361. 
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. 
CA A Cancer Journal for Clinicians, 55(2), 74-108. 
Pearce, C. L., Wu, A. H., Gayther, S. A., Bale, A. E., Beck, P. A., Beesley, J., et al. 
(2008). Progesterone receptor variation and risk of ovarian cancer is limited to the 
invasive endometrioid subtype: results from the Ovarian Cancer Association 
Consortium pooled analysis. British Journal of Cancer, 98(2), 282-288. 
Pharoah, P. D., & Ponder, B. A. (2002). The genetics of ovarian cancer. Best Practice 
& Research: Clinical Obstetrics & Gynaecology, 16(4), 449-468. 
Pike, M. C., Pearce, C. L., Peters, R., Cozen, W., Wan, P., & Wu, A. H. (2004). 
Hormonal factors and the risk of invasive ovarian cancer: a population-based case-
control study. Fertility and Sterility, 82(1), 186-195. 
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000). Fibroblast growth factors, 
their receptors and signaling. Endocrine- Related Cancer, 7(3), 165-197. 
 17
Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005). 
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 
Cytokine & Growth Factor Reviews, 16(2), 159-178. 
Purcell, S., Cherny, S. S., & Sham, P. C. (2003). Genetic Power Calculator: design of 
linkage and association genetic mapping studies of complex traits. Bioinformatics, 
19(1), 149-150. 
Rossing, M. A., Cushing-Haugen, K. L., Wicklund, K. G., Doherty, J. A., & Weiss, N. 
S. (2007). Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer 
Epidemiology Biomarkers & Prevention, 16(12), 2548-2556. 
Sellers, T. A., Huang, Y., Cunningham, J., Goode, E. L., Sutphen, R., Vierkant, R. A., 
et al. (2008). Association of single nucleotide polymorphisms in glycosylation genes 
with risk of epithelial ovarian cancer. Cancer Epidemiology Biomarkers & Prevention, 
17(2), 397-404. 
Weidner, N. (1995). Intratumour microvessel density as a prognostic factor in cancer. 
American Journal of Pathology, 147(1), 9-19. 
Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., & Folkman, J. (1993). Tumour 
angiogenesis correlates with metastasis in invasive prostate carcinoma. American 
Journal of Pathology, 143(2), 401-409. 
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991). Tumour 
angiogenesis and metastasis--correlation in invasive breast carcinoma. New England 
Journal of Medicine, 324(1), 1-8. 
Wenham, R. M., Lancaster, J. M., & Berchuck, A. (2002). Molecular aspects of 
ovarian cancer. Best Practice & Research: Clinical Obstetrics & Gynaecology, 16(4), 
483-497. 
 18
Whittemore, A. S. (1994). Characteristics relating to ovarian cancer risk: implications 
for prevention and detection. Gynecologic Oncology, 55(3 Pt 2), S15-19. 
 
 
 
 
 
 
 
 
 19
Table 1:  Description of study populations according to contributing OCAC study 
 
Study 
(Location) 
Case ascertainment Cases Control 
ascertainment 
Controls
 Total
Numbera 
Ageb
(Mean ± Std. 
Dev.) 
Primary Sited 
(ovary/tubal/
primary 
peritoneal) 
 
FIGO Stagee 
(I/II/III/IV) 
Total
Numbera 
Ageb
 (Mean ± Std. 
Dev.) 
AOCS-ACS 
(Australia) 
Surgical treatment 
centres throughout 
Australia, and cancer 
registries of Queensland, 
South and Western 
Australia, New South 
Wales and Victoria;  
 
549 (476) 60.4 (±10.1) 381/22/73 33/28/333/56 Population based: 
Commonwealth 
Electoral roll 
1,028 (946) 57.4 (±11.6) 
MAYO (USA) Cases attending the 
Mayo Clinic from six 
surrounding states 
124 (124) *63.0 (±11.9) 124/0/0 8/3/85/27 Clinic based: 
Women seeking 
general exams at 
Mayo Clinic  
60 (60) *62.5 (±12.5) 
 
DOVE (USA)  Cancer Surveillance 
System, SEERc 
298 (274) 59.0 (±8.6) 
 
298/0/0 n/a Population based: 
Random digit 
dialling 
726 (652) 55.9 (±9.5) 
 
HOPE (USA) Registries, physician 
offices, pathology 
databases 
168 (161) 60.1 (±11.3) 
 
168/0/0 n/a Population based: 
Random digit 
dialling 
702 (671) 57.6 (±10.3) 
 
USC (USA)  Los Angeles Cancer 
Surveillance Program 
318 (234) 59.3 (±10.9) 318/0/0 n/a Population based: 
Neighbourhood 
recruits 
621 (500) 55.7 (±12.9) 
Totals --- 1457 (1269) 60.1 (±10.3)   --- 3137 (2829) 56.9 (±11.2) 
a:  All serous invasive cases with genotype data available for analysis, with the number of non-Hispanic White in parentheses 
b:  Age of Non-Hispanic White serous cases (age at diagnosis) and controls (age at interview); mean and standard deviation based on total number; * no significant difference 
(p≤0.05) between mean age of cases and controls 
c:  SEER, Surveillance Epidemiology and End Results 
d:  Primary site of tumour among non-Hispanic White case (numbers may not sum to N because of missing data) 
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e:  Stage of tumour among non-Hispanic White case (numbers may not sum to N because of missing data) 
n/a – not available 
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Table 2: Risk estimates for the 25 FGF2 SNPs among non-Hispanic White women with serous carcinoma 
 
SNPid  Heterozygotes Rare Homozygotes Per-Allele 
MAFa Controls/Casesb  ORc 95%  CI P-
value 
ORc 95%  CI P-
value 
ORc 95%  CI P-
value 
rs10003827d 0.14 1,823 667 0.82 (0.66 - 1.02) 0.08 1.00 (0.52 - 1.92) 0.99 0.87 (0.72 - 1.05) 0.14 
rs10452197 0.14 2,816 1,265 0.99 (0.84 - 1.16) 0.87 1.37 (0.88 - 2.13) 0.16 1.04 (0.91 - 1.19) 0.55 
rs11737764d 0.09 1,821 668 1.15 (0.91 - 1.45) 0.24 0.82 (0.30 - 2.26) 0.71 1.10 (0.89 - 1.36) 0.37 
rs11938826 0.16 2,818 1,256 0.95 (0.81 - 1.11) 0.49 0.82 (0.53 - 1.29) 0.39 0.94 (0.82 - 1.07) 0.32 
rs12506776 0.17 2,823 1,266 0.91 (0.78 - 1.06) 0.25 0.93 (0.63 - 1.38) 0.71 0.93 (0.82 - 1.06) 0.27 
rs1476214 0.38 2,821 1,267 0.95 (0.82 - 1.09) 0.45 0.90 (0.73 - 1.10) 0.29 0.95 (0.86 - 1.04) 0.26 
rs1476217d 0.37 1,822 669 0.84 (0.69 - 1.02) 0.08 0.88 (0.67 - 1.15) 0.35 0.91 (0.80 - 1.04) 0.16 
rs 167428 0.27 2,826 1,267 1.03 (0.90 - 1.19) 0.64 0.94 (0.72 - 1.22) 0.63 1.00 (0.90 - 1.11) 0.96 
rs17407577 0.06 2,828 1,269 0.89 (0.72 - 1.10) 0.29 2.63 (0.80 - 8.67) 0.11 0.95 (0.78 - 1.16) 0.61 
rs17473132 0.07 2,536 1,159 1.20 (0.98 - 1.46) 0.08 0.18 (0.02 - 1.40) 0.10 1.11 (0.92 - 1.35) 0.26 
rs1960669 0.14 2,825 1,267 0.93 (0.79 - 1.09) 0.39 1.16 (0.72 - 1.88) 0.53 0.97 (0.85 - 1.12) 0.69 
rs308379 0.39 2,825 1,268 0.85 (0.74 - 0.98) 0.03 0.94 (0.77 - 1.16) 0.59 0.94 (0.85 - 1.04) 0.22 
rs308382 0.16 2,822 1,269 0.92 (0.78 - 1.07) 0.26 1.18 (0.78 - 1.77) 0.43 0.97 (0.85 - 1.10) 0.63 
rs308420 0.09 2,819 1,265 0.97 (0.81 - 1.17) 0.76 1.43 (0.71 - 2.89) 0.32 1.01 (0.86 - 1.20) 0.89 
rs308428 0.14 2,826 1,268 0.99 (0.84 - 1.15) 0.86 0.95 (0.58 - 1.54) 0.82 0.98 (0.86 - 1.13) 0.80 
rs308435d 0.15 1,822 669 0.87 (0.71 - 1.07) 0.20 1.14 (0.68 - 1.93) 0.62 0.94 (0.79 - 1.11) 0.46 
rs308439 0.04 2,805 1,256 0.97 (0.76 - 1.24) 0.83 na na na na 0.92 (0.73 - 1.17) 0.51 
rs308441 0.20 2,821 1,266 1.03 (0.89 - 1.19) 0.69 0.93 (0.65 - 1.33) 0.70 1.00 (0.89 - 1.13) 0.94 
rs308443 0.03 2,823 1,266 0.96 (0.71 - 1.28) 0.77 na na na na 0.91 (0.68 - 1.21) 0.51 
rs308447d 0.38 1,819 667 0.72 (0.59 - 0.87) 0.001 0.88 (0.67 - 1.16) 0.37 0.87 (0.76 - 1.00) 0.04 
rs3789138e 0.42 996 598 1.13 (0.89 - 1.42) 0.32 0.89 (0.65 - 1.21) 0.44 0.97 (0.84 - 1.13) 0.70 
rs3804158 0.45 2,819 1,255 1.01 (0.86 - 1.18) 0.92 0.92 (0.76 - 1.11) 0.37 0.96 (0.88 - 1.06) 0.42 
rs6819187d 0.44 1,821 667 0.89 (0.73 - 1.09) 0.27 0.92 (0.71 - 1.19) 0.51 0.95 (0.84 - 1.08) 0.42 
rs7694627d 0.17 1,823 669 0.97 (0.79 - 1.18) 0.76 1.01 (0.59 - 1.74) 0.96 0.98 (0.83 - 1.16) 0.83 
rs7700205 0.17 2,825 1,268 1.03 (0.89 - 1.19) 0.72 1.05 (0.71 - 1.54) 0.81 1.03 (0.91 - 1.16) 0.69 
 “na” represents SNPs with insufficient homozygote numbers for calculation of risk estimates; bold indicates p < 0.05 
a:  Minor allele frequency estimated from control population  
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b:  Sample sizes reflect differences in genotype data available for analysis and exclusions based on HWE threshold   
c:  Odds Ratios  (ORs) are adjusted for study and age (at interview for controls; at diagnosis for cases). Reference genotypes for case-control comparisons are common 
homozygotes  
d:  Indicates SNPs genotyped for DOVE, HOPE and USC studies only 
e:  Indicates SNPs genotyped for AOCS-ACS study only 
 
